Cow's Milk Allergy Clinical Trial
Official title:
Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy
The investigators aim to assess the tolerance to a new commercially available Aaf in children affected by IgE- or non-IgE-mediated CMA.
Prospective controlled study including pediatric patients (≤14 years of age) with a recent
diagnosis of IgE- or non-IgE-mediated CMA, confirmed by positive oral food challenge or
anaphylaxis in the 2 months prior to enrollment and under good clinical control. Children
with concomitant chronic systemic diseases, congenital cardiac defects, active tuberculosis,
autoimmune diseases, immunodeficiency, chronic inflammatory bowel diseases, celiac disease,
cystic fibrosis, metabolic diseases, lactose intolerance, malignancy, chronic pulmonary
diseases, malformations of the gastrointestinal tract, gastroesophageal reflux disease
non-food allergy-related, suspected eosinophilic gastrointestinal disorders, were excluded.
At the first evaluation, the clinical history, information on allergic disease and baseline
clinical conditions were assessed by 3 experienced pediatric allergists and the child was
invited to participate in the study. At least one parent of each subject provided written
informed consent. Children with atopic dermatitis were included if it was under sufficient
control to allow recognition of a positive response to the challenge. Infants and children
using a betablocker within 12 hours of the challenge, and short-acting, medium-acting, or
long-acting antihistamines more than once within 3, 7, or 21 days of DBPCFC, respectively,
or oral steroids within 21 days of oral food challenge were excluded from study. Adverse
events were recorded throughout the study.
Food allergy screening tests Measurement of serum specific IgE against CMP
(alpha-lactalbumin, ALA; beta-lactoglobulin, BLG; and casein); skin prick tests (SPT) with
whole milk, CMP, placebo formula (another commercially available Aaf, Neocate, Nutricia,
Milan, Italy) and study formula (Sineall, Humana, Milan, Italy); and atopy patch tests (APT)
with whole milk, placebo and study formula, were performed on all patients.
Serum samples from patients were analysed for specific IgE antibody titers against CMP using
a commercially available kit (CAP-RAST, Pharmacia Diagnostics AB, Uppsala Sweden). The
detection limit of the system was 0.35 kU/L IgE. Subjects were deemed sensitised if their
specific IgE levels exceeded the detection limit.
Skin prick tests were performed using a 1-mm single peak lancet (ALK, Copenhagen, Denmark),
with histamine dihydrochloride (10 mg/ml) and isotonic saline solution (NaCl 0.9%) as
positive and negative control, respectively. Reactions were recorded on the basis of the
largest diameter (in millimetres) of the wheal and flare at 15 min. The SPT result were
considered "positive" if the wheal was 3 mm or larger, without reaction of the negative
control.
Atopy patch tests were performed as previously reported. Briefly, we used 1 drop (50 μl) of
fresh milk put on filter paper and applied with adhesive tape to the unaffected skin of the
child's back, using 12-mm aluminium cups (Finn Chambers on Scan pore; Epitest Ltd Oy,
Tuusula, Finland). Isotonic saline solution was the negative control. The occlusion time was
48 h and results were read 20 min and 24 h after removal of the cups. To exclude false
positive reactions, we also tested allergens in a 1:10 solution. Seventy-two hours after the
start of the test, reactions were classified as follows: - negative; +/- doubtful: erythema
only; + weak positive: erythema, slight infiltration, papules; ++ strong positive: erythema,
infiltration, papules, little vesicles; +++ very strong positive: erythema, large confluent
vesicles in bubbles. Children and their families were requested to report any delayed skin
reaction that was noticed after this time. Irritant or doubtful reactions, including sharply
demarcated confluent erythema, or reactions confined to margins without infiltration, were
deemed negative.
Oral food challenge All food challenges were performed in a double blind placebo controlled
food challenge (DBPCFC) manner, and took place in the outpatients clinic on 2 separate days
with a one week interval, as previously reported. A 7-day period of strict elimination of
CMP and other suspected food allergens preceded the DBPCFC. The results were assessed
simultaneously by 3 experienced pediatric allergists in each center. Randomization and
preparation of the challenges were performed by clinical dieticians not directly involved in
the study; a separate computer-generated randomization list of participant numbers that
indicated in order in which each study formula should be offered in the DBPCFC challenge was
created.
Briefly, every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo
(the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula
(Sineall, Humana, Milan, Italy) were administered. Full emergency equipment and drugs
(epinephrine, antihistamines, and steroids) were at hand. Study subjects were scored for
nine items divided into four main categories (general, skin, gastrointestinal, and
respiratory) on a 0- to 3-point scale (0, none; 1, light; 2, moderate; and 3, severe). If at
least two of the 3 specialists independently scored any item at level 3, or 2 (or more)
items at level 2, the test result was considered positive. The patients were observed for 2
h after the final dose, and then discharged. In the case of a positive DBPCFC, at any
testing dose, the patient remained under observation until after symptoms resolved. If
patients did not show any symptoms within the first 24 hours, to assess long-term tolerance
and reveal any false-negative results to the challenges, parents were advised to administer
to the patients one single top dose of the tested formula (verum or placebo) everyday at
home for seven days (7-day home feeding period). Participants' parents recorded in a daily
diary volume of formula consumed; presence and severity of vomiting, diarrhea, rash, runny
nose, wheezing, or any other symptoms (rated as mild, moderate, or excessive); and number of
bowel movements. If any symptoms occurred during this period, the patients returned to the
outpatient clinic on the same day. The investigator completed a final evaluation at the end
of the 7-day home feeding period. After 7-day home feeding period of verum or placebo
administration, the patients were examined and the parents interviewed at the Centers. To
rule out false-negative challenge result parents were asked to contact the Center if any
symptoms occurred in the following 7 days after the DBPCFC procedures. The challenge was
considered negative if the patient tolerated the entire challenge, including the observation
period.Markers of intestinal mucosa inflammation The fecal concentration of calprotectin
(FC) and of eosinophilic cationic protein (ECP) was determined 24 hours before and 7 and 14
days after DBPCFC to evaluate the occurrence of even subclinical intestinal mucosa
inflammation in response to Aaf exposure. Stool samples were collected, stored at -20°C and
analyzed at the end of the study by a researcher blinded to the results of DBPCFC. Fecal
calprotectin levels were measured by a highly sensitive enzyme-linked immunosorbent assay
(ELISA, Calprest®, Eurospital, Italy).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02738060 -
The Effect of Baked Milk on Cow's Milk Allergy
|
Phase 2 | |
Recruiting |
NCT02149134 -
Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy
|
Phase 2 | |
Recruiting |
NCT01891916 -
Effect Of Lactobacillus GG on Atopic March
|
N/A | |
Completed |
NCT01634490 -
Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy
|
N/A | |
Completed |
NCT02466035 -
Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA)
|
N/A | |
Completed |
NCT02379598 -
Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy
|
N/A | |
Completed |
NCT04330092 -
Diagnosis of Cow's Milk Protein Allergy
|
||
Not yet recruiting |
NCT02081651 -
Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy
|
Phase 3 | |
Completed |
NCT03462030 -
Baked Milk Oral Immunotherapy for Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT02465905 -
Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study
|
N/A | |
Suspended |
NCT05731206 -
Hypoallergenicity of a Hydrolyzed Protein Infant Formula
|
N/A | |
Not yet recruiting |
NCT06456541 -
Infant Formula in Infants and Children With Cow's Milk Allergy
|
N/A | |
Recruiting |
NCT02062476 -
Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT01589731 -
Polymerized Beta-lactoglobulin Comparative Immunoreactivity
|
N/A | |
Terminated |
NCT02405923 -
Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy
|
N/A | |
Terminated |
NCT04910373 -
Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy
|
N/A | |
Recruiting |
NCT01968278 -
Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients
|
N/A | |
Withdrawn |
NCT01470768 -
Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas
|
N/A | |
Recruiting |
NCT05883384 -
Validity of Cow's Milk-related Symptom Score Among Children Suspected to Have Cow's Milk Protein Alergy
|
||
Completed |
NCT01901380 -
Cow's Milk Allergy and Functional Gastrointestinal Disorders
|
N/A |